Cargando…

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of breast cancer susceptibility genes 1 and 2 (BRCA1/2) mutant ovarian and breast cancers, and are now being evaluated in metastatic castration-resistant prostate cancer (mCRPC). Reversion mutations that restor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simmons, Andrew D., Nguyen, Minh, Pintus, Elias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071565/ https://www.ncbi.nlm.nih.gov/pubmed/32171277 http://dx.doi.org/10.1186/s12885-020-6657-2

Ejemplares similares

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib
por: Petrylak, Daniel P., et al.
Publicado: (2022)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
por: Gaur, Abhay Singh
Publicado: (2022)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
por: Kondrashova, Olga, et al.
Publicado: (2018)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
por: Rosar, Florian, et al.
Publicado: (2022)

Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
por: Qiu, Ping, et al.
Publicado: (2019)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Gamat-Huber, Melissa, et al.
Publicado: (2020)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
por: Cantó, Elisabet, et al.
Publicado: (2023)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
por: Dockery, LE, et al.
Publicado: (2017)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018)

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
por: Teo, Min Yuen, et al.
Publicado: (2018)

Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients
por: León-Mateos, Luis, et al.
Publicado: (2017)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling
por: Zhang, Xiong, et al.
Publicado: (2021)

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions
por: Scott, Rodney J., et al.
Publicado: (2021)

Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance
por: Khalil, Md Imtiaz, et al.
Publicado: (2022)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort
por: Ferriero, Mariaconsiglia, et al.
Publicado: (2023)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
por: Moreira, Raphael B., et al.
Publicado: (2017)

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
por: Kessel, Katharina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rdfiaa6vjrhfmttc6ngrahoblt